133 related articles for article (PubMed ID: 6655548)
1. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients.
Uchino K; Isozaki S; Amano J; Tanaka N; Saitoh Y; Nakagawa F; Tamura Z; Oka H
J Pharmacobiodyn; 1983 Sep; 6(9):684-91. PubMed ID: 6655548
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers.
Ogata H; Zugarni S; Ejima A; Kawatsu Y
Eur J Clin Pharmacol; 1983; 24(6):791-6. PubMed ID: 6688397
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of furosemide in patients with hepatic cirrhosis.
González G; Arancibia A; Rivas MI; Caro P; Antezana C
Eur J Clin Pharmacol; 1982; 22(4):315-20. PubMed ID: 7106167
[TBL] [Abstract][Full Text] [Related]
4. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
[TBL] [Abstract][Full Text] [Related]
5. The pharmaceutical and biological availability of commercial preparations of furosemide.
Stüber W; Mutschler E; Steinbach D
Arzneimittelforschung; 1982; 32(6):693-7. PubMed ID: 6889429
[TBL] [Abstract][Full Text] [Related]
6. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
Otsuka K; Wagner C; Selen A; Dressman J
J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients.
Imai Y; Abe K; Sasaki S; Nihei M; Sekino H; Yoshinaga K
Tohoku J Exp Med; 1986 Apr; 148(4):421-38. PubMed ID: 3738908
[TBL] [Abstract][Full Text] [Related]
8. Furosemide kinetics and dynamics in patients with cirrhosis.
Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs.
Koh SK; Jeong JW; Choi SI; Kim RM; Koo TS; Cho KH; Seo KW
BMC Vet Res; 2021 Sep; 17(1):295. PubMed ID: 34488750
[TBL] [Abstract][Full Text] [Related]
11. [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].
Cho HS; Park GT; Kim YH; Shim SG; Kim JB; Lee OY; Choi HS; Hahm JS; Lee MH
Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):324-31. PubMed ID: 14695699
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.
Hammarlund MM; Paalzow LK; Odlind B
Eur J Clin Pharmacol; 1984; 26(2):197-207. PubMed ID: 6723758
[TBL] [Abstract][Full Text] [Related]
13. Furosemide disposition in cirrhosis.
Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.
Loew D; Barkow D; Schuster O; Knoell HE
Eur J Clin Pharmacol; 1984; 26(2):191-5. PubMed ID: 6723757
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men.
Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT
Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and pharmacokinetic study of a slow-release formulation of furosemide in man.
Ebihara A; Tawara K; Oka T
Arzneimittelforschung; 1983; 33(1):163-6. PubMed ID: 6681970
[TBL] [Abstract][Full Text] [Related]
17. Quantitative determination of furosemide in plasma, plasma water, urine and ascites fluid by high-performance liquid chromatography.
Uchino K; Isozaki S; Saitoh Y; Nakagawa F; Tamura Z; Tanaka N
J Chromatogr; 1984 Jun; 308():241-9. PubMed ID: 6746817
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
Schuster O; Loew D; Knoell HE
Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
[TBL] [Abstract][Full Text] [Related]
20. Furosemide kinetics in patients with hepatic cirrhosis with ascites.
Fuller R; Hoppel C; Ingalls ST
Clin Pharmacol Ther; 1981 Oct; 30(4):461-7. PubMed ID: 7285480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
